| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000038420 |
| Receipt No. | R000043781 |
| Scientific Title | Effect of high-frequency rTMS on patients with leg paralysis |
| Date of disclosure of the study information | 2021/07/07 |
| Last modified on | 2019/10/29 (Ver. 1) |
| Basic information | ||
| Public title | Effect of high-frequency rTMS on patients with leg paralysis | |
| Acronym | Effect of high-frequency rTMS on patients with leg paralysis | |
| Scientific Title | Effect of high-frequency rTMS on patients with leg paralysis | |
| Scientific Title:Acronym | Effect of high-frequency rTMS on patients with leg paralysis | |
| Region |
|
|
| Condition | ||
| Condition | Stroke | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Verification of the effects of high frequency repetitive transcranial magnetic stimulation on lower limb paralysis in stroke patients |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Brunnstrom recovery stage
Fugl-Meyer assessment Modified Ashworth Scale Functional Reach Test Timed Up and Go test 10m gait Functional balance scale BESTEST Functional Ambulation Categories Functional Independence Measure |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | High-frequency repetitive transcranial magnetic stimulation on lower limb area | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The lesion does not extend to the cerebral cortex
In the case of cerebral hemorrhage after 0 days after onset, hematoma is absorbed 10m walk is possible by walking alone (balance ability is not included. Contact assistance is also possible) No history of epilepsy or seizures Metals close to the stimulation site (stimulators such as cochlear implants, magnetic clips, deep brain stimulation and vagus nerve stimulation), without a cardiac pacemaker Intracranial titanium products, or magnetically mounted dentures, without implants Intracranial lesions at risk for seizures There is no Those who have not taken medications that lower the seizure threshold (such as tricyclic antidepressants, maprotiline, theophylline, methylphenidate, ketamine, clozapine, zotepine). Those who are not complicated by serious physical illness during pregnancy, abuse, withdrawal of alcohol, caffeine or stimulant. Those who do not have cognitive decline or higher brain damage that may affect or be dangerous in the intervention of this study |
|||
| Key exclusion criteria | The lesion does not extend to the cerebral cortex
In the case of cerebral hemorrhage after 0 days after onset, hematoma is absorbed 10m walk is possible by walking alone (balance ability is not included. Contact assistance is also possible) No history of epilepsy or seizures Metals close to the stimulation site (stimulators such as cochlear implants, magnetic clips, deep brain stimulation and vagus nerve stimulation), without a cardiac pacemaker Intracranial titanium products, or magnetically mounted dentures, without implants Intracranial lesions at risk for seizures There is no Those who have not taken medications that lower the seizure threshold (such as tricyclic antidepressants, maprotiline, theophylline, methylphenidate, ketamine, clozapine, zotepine). Those who are not complicated by serious physical illness during pregnancy, abuse, withdrawal of alcohol, caffeine or stimulant. Those who do not have cognitive decline or higher brain damage that may affect or be dangerous in the intervention of this study |
|||
| Target sample size | 10 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical Corporation Motoyama rehabilitation
Hospital |
||||||
| Division name | rehabilitation | ||||||
| Zip code | 6580015 | ||||||
| Address | 7-7-15 motoyamaminami-cho,hidgashinada-ku kobe-shi hyogo-ken | ||||||
| TEL | 0784128080 | ||||||
| sako19920707@gmail.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Motoyama Rehabilitation Hospital | ||||||
| Division name | rehabilitation | ||||||
| Zip code | 6580015 | ||||||
| Address | 7-7-15 motoyamaminami-cho,hidgashinada-ku kobe-shi hyogo-ken | ||||||
| TEL | 0784128080 | ||||||
| Homepage URL | |||||||
| sako19920707@gmail.com | |||||||
| Sponsor | |
| Institute | Motoyama Rehabilitation Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Motoyama Rehabilitation Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Motoyama Rehabilitation Hospital |
| Address | 7-7-15 motoyamaminami-cho,hidgashinada-ku kobe-shi hyogo-ken |
| Tel | 0784128080 |
| sako19920707@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043781 |